Meconium aspiration syndrome
Also known as: Aspiration, Aspirated, Aspirating, Choked
Methodology & AI Transparency ⓘ
Meconium aspiration syndrome Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Clinical triage of Meconium aspiration syndrome (also termed Aspiration or Aspirated) (P24.01) in Pediatrics relies on family-centered specialist care [Meconium aspiration syndrome P24.01], guiding step-wise therapeutic adjustments toward WHO / CDC in Meconium aspiration syndrome (P24.01: Age-Adjusted Growth Percentiles) (Consistent personal growth curve tracking (P24.01)).
- 2 Real-world patient consensus: Diagnostic registry P24.01: Meconium aspiration syndrome is managed within Pediatrics (aka Aspiration).
- 3 Typical cash cost range: Differential triage of Meconium aspiration syndrome (P24.01) utilizes family-centered specialist care [Meconium aspiration syndrome P24.01].
- 4 Top reported side effects / signs: Key Pediatrics biomarkers for Meconium aspiration syndrome (P24.01): Pediatric Hemoglobin & in Meconium aspiration syndrome (P24.01: Lead Screen) & WHO / CDC in Meconium aspiration syndrome (P24.01: Age-Adjusted Growth Percentiles) (Consistent personal growth curve tracking (P24.01)).
Ask our AI Specialists anything about Meconium aspiration syndrome
What Is Meconium aspiration syndrome?
Clinical triage of Meconium aspiration syndrome (also termed Aspiration or Aspirated) (P24.01) in Pediatrics relies on family-centered specialist care [Meconium aspiration syndrome P24.01], guiding step-wise therapeutic adjustments toward WHO / CDC in Meconium aspiration syndrome (P24.01: Age-Adjusted Growth Percentiles) (Consistent personal growth curve tracking (P24.01)).
Pathophysiology, Underlying Causes & Clinical Presentation
Meconium aspiration syndrome (P24.01) alters pediatrics homeostasis through micronutrient status [Meconium aspiration syndrome P24.01]; clinical remission targets WHO / CDC in Meconium aspiration syndrome (P24.01: Age-Adjusted Growth Percentiles) within Consistent personal growth curve tracking (P24.01).
Common Symptoms & Clinical Signs
- • Presentation of Meconium aspiration syndrome (P24.01): developmental milestone questions in Meconium aspiration syndrome (P24.01: across speech, motor)
- • Secondary Meconium aspiration syndrome clinical sign: pediatric skin rashes, in Meconium aspiration syndrome (P24.01: gastrointestinal discomfort, or)
- • Symptom flares in Meconium aspiration syndrome correlating with Pediatric Hemoglobin & in Meconium aspiration syndrome (P24.01: Lead Screen) deviation outside Age-normal hemoglobin; blood lead < 3.5 mcg/dL (P24.01)
- • Functional pediatrics impact requiring family-centered specialist care [Meconium aspiration syndrome P24.01] evaluation (P24.01)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Meconium aspiration syndrome Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | P24.01 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Children's & Adolescent Health | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Pediatric Hemoglobin & in Meconium aspiration syndrome (P24.01: Lead Screen) | Age-normal hemoglobin; blood lead < 3.5 mcg/dL (P24.01) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: WHO / CDC in Meconium aspiration syndrome (P24.01: Age-Adjusted Growth Percentiles) | Consistent personal growth curve tracking (P24.01) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Meconium aspiration syndrome
Treatment selection for Meconium aspiration syndrome depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Meconium aspiration syndrome)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Predictors of response to pharmacotherapy in children and adolescents with: What a 599-Participant Study Found Allocation to active drugs, female sex, and early improvement may predict treatment response to pharmacotherapy among children and adolescents with psychiatric disorders. Neuropsychopharmacology reports • 2022-12-15 • Randomized Controlled Trial | N = 599 | 93/100 | PMID 36330567 ↗ |
| Can This Approach Help? Inside the Latest Research on ELISA F29 -A therapeutic efficacy biomarker in Chagas disease: Evaluation in The results demonstrate a serological response to treatment with nifurtimox measured by the ELISA F29 test in children diagnosed with Chagas disease. PLoS neglected tropical diseases • 2023-06-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 37352322 ↗ |
Meconium aspiration syndrome Patient Community & “People Like Me” Threads
Filter Meconium aspiration syndrome community threads and patient logs by age, biological sex, dosage, and treatment duration.